Skip to main
DRIO

DarioHealth (DRIO) Stock Forecast & Price Target

DarioHealth (DRIO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

DarioHealth is a leading digital therapeutics company, utilizing proprietary data, devices, and AI to provide personalized interventions and coaching for chronic conditions. With strong gross margins and a growing contracted ARR, the company is well-positioned for sustained growth and eventual profitability. However, there are potential risks associated with government-driven HCIT spending and competition in the industry.

Bears say

DarioHealth is a digitally focused company with a vertically integrated health intelligence platform and a potential for expansion through cross-selling to legacy customers. While their recent expansion with a national health plan and a Fortune 50 company show promising commercial progress, there are potential risks associated with the HCIT space that could slow growth and impact profitability. With a focus on cost management, DarioHealth may have improved its financials, but a challenging digital health demand environment and limited growth visibility in certain channels may present challenges for the company's future success.

DarioHealth (DRIO) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DarioHealth and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DarioHealth (DRIO) Forecast

Analysts have given DarioHealth (DRIO) a Buy based on their latest research and market trends.

According to 3 analysts, DarioHealth (DRIO) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DarioHealth (DRIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.